Knowthestock.com
CBLI - Cleveland BioLabs Inc

Sell

Weak GrowthEarnings/Profit is Negative

21%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -90.02%
Operating Income is Negative
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -2196.49%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 1.0
Debt Ratio is 0.04
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Cleveland BioLabs Inc (CBLI) - www.cbiolabs.com
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Cleveland BioLabs' proprietary platform of Toll-like immune receptor activators addresses conditions such as radiation sickness and cancer treatment side effects. Cleveland Biolabs' most advanced product candidate, Entolimod is being developed as a medical radiation countermeasure for preventing death from acute radiation syndrome and, through its joint venture with Everon Biosciences, LLC - Genome Protection, Inc. - for other anticancer and antiaging indications. Additionally, Cleveland BioLabs also conducts business in the Russian Federation through a joint venture with Joint Stock Company RUSNANO, Panacela Labs, Inc. Cleveland BioLabs maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute.
Exchange - NASDAQ CAPITAL MARKET
Industry - Research and Development in Biotechnology
Sector - Professional, Scientific, and Technical Services
CEO -
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.